#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=This study showed that the cotreatment of G. lucidum extracts ( GLE ) and quercetin ( QCT ) exerted synergistic antitumor and antiviral activities against SNU719 EBVaGC cells .
3-1	15-19	This	abstract[3]	new[3]	coref	21-12[152_3]
3-2	20-25	study	abstract[3]	new[3]	_	_
3-3	26-32	showed	_	_	_	_
3-4	33-37	that	_	_	_	_
3-5	38-41	the	abstract[4]	new[4]	coref	4-4[18_4]
3-6	42-53	cotreatment	abstract[4]	new[4]	_	_
3-7	54-56	of	abstract[4]	new[4]	_	_
3-8	57-59	G.	abstract[4]|person|substance[7]	new[4]|new|new[7]	appos|appos	3-12[0_7]|3-12[0_7]
3-9	60-67	lucidum	abstract[4]|event|substance[7]	new[4]|new|new[7]	_	_
3-10	68-76	extracts	abstract[4]|substance[7]	new[4]|new[7]	_	_
3-11	77-78	(	_	_	_	_
3-12	79-82	GLE	substance	giv	coref	7-14
3-13	83-84	)	_	_	_	_
3-14	85-88	and	_	_	_	_
3-15	89-98	quercetin	substance	new	appos	3-17
3-16	99-100	(	_	_	_	_
3-17	101-104	QCT	substance	giv	coref	5-9
3-18	105-106	)	_	_	_	_
3-19	107-114	exerted	_	_	_	_
3-20	115-126	synergistic	abstract[11]|abstract[12]	new[11]|new[12]	coref|coref|coref|coref	13-3[0_11]|17-3[124_12]|13-3[0_11]|17-3[124_12]
3-21	127-136	antitumor	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-22	137-140	and	abstract[12]	new[12]	_	_
3-23	141-150	antiviral	abstract[12]|abstract[13]	new[12]|new[13]	coref	17-6[125_13]
3-24	151-161	activities	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-25	162-169	against	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-26	170-176	SNU719	abstract[12]|abstract[13]|substance|object[16]	new[12]|new[13]|new|new[16]	coref|coref|coref|coref	4-15|4-15[22_16]|4-15|4-15[22_16]
3-27	177-183	EBVaGC	abstract[12]|abstract[13]|substance|object[16]	new[12]|new[13]|new|new[16]	coref	15-1
3-28	184-189	cells	abstract[12]|abstract[13]|object[16]	new[12]|new[13]|new[16]	_	_
3-29	190-191	.	_	_	_	_

#Text=Low concentrations of the cotreatment resulted in both the synergistic activation of cytotoxicity in SNU719 cells and the suppression of tumor development in MKN1-EBV xenograft mice .
4-1	192-195	Low	abstract[17]	new[17]	_	_
4-2	196-210	concentrations	abstract[17]	new[17]	_	_
4-3	211-213	of	abstract[17]	new[17]	_	_
4-4	214-217	the	abstract[17]|abstract[18]	new[17]|giv[18]	coref	8-8[53_18]
4-5	218-229	cotreatment	abstract[17]|abstract[18]	new[17]|giv[18]	_	_
4-6	230-238	resulted	abstract	new	coref|none	21-3[148_0]|4-6[0_170]
4-7	239-241	in	_	_	_	_
4-8	242-246	both	abstract[19]	new[19]	_	_
4-9	247-250	the	abstract[19]	new[19]	_	_
4-10	251-262	synergistic	abstract[19]	new[19]	_	_
4-11	263-273	activation	abstract[19]	new[19]	_	_
4-12	274-276	of	abstract[19]	new[19]	_	_
4-13	277-289	cytotoxicity	abstract[19]|abstract[20]	new[19]|new[20]	coref	5-11[33_20]
4-14	290-292	in	abstract[19]|abstract[20]	new[19]|new[20]	_	_
4-15	293-299	SNU719	abstract[19]|abstract[20]|substance|object[22]	new[19]|new[20]|giv|giv[22]	coref|coref|coref|coref	4-6|5-17[36_22]|4-6|5-17[36_22]
4-16	300-305	cells	abstract[19]|abstract[20]|object[22]	new[19]|new[20]|giv[22]	_	_
4-17	306-309	and	_	_	_	_
4-18	310-313	the	event[23]	new[23]	_	_
4-19	314-325	suppression	event[23]	new[23]	_	_
4-20	326-328	of	event[23]	new[23]	_	_
4-21	329-334	tumor	event[23]|abstract|event[25]	new[23]|new|new[25]	_	_
4-22	335-346	development	event[23]|event[25]	new[23]|new[25]	_	_
4-23	347-349	in	event[23]|event[25]	new[23]|new[25]	_	_
4-24	350-358	MKN1-EBV	event[23]|event[25]|animal|animal[28]	new[23]|new[25]|new|new[28]	_	_
4-25	359-368	xenograft	event[23]|event[25]|animal|animal[28]	new[23]|new[25]|new|new[28]	_	_
4-26	369-373	mice	event[23]|event[25]|animal[28]	new[23]|new[25]|new[28]	_	_
4-27	374-375	.	_	_	_	_

#Text=The addition of a low concentration GLE to QCT reinforced QCT-mediated cytotoxicity and QCT-mediated apoptosis in SNU719 cells .
5-1	376-379	The	abstract[29]	new[29]	coref	6-3[37_29]
5-2	380-388	addition	abstract[29]	new[29]	_	_
5-3	389-391	of	abstract[29]	new[29]	_	_
5-4	392-393	a	abstract[29]|abstract[30]|substance[31]	new[29]|new[30]|new[31]	_	_
5-5	394-397	low	abstract[29]|abstract[30]|substance[31]	new[29]|new[30]|new[31]	_	_
5-6	398-411	concentration	abstract[29]|abstract[30]|substance[31]	new[29]|new[30]|new[31]	_	_
5-7	412-415	GLE	abstract[29]|substance[31]	new[29]|new[31]	_	_
5-8	416-418	to	abstract[29]|substance[31]	new[29]|new[31]	_	_
5-9	419-422	QCT	abstract[29]|substance[31]|substance	new[29]|new[31]|giv	coref	7-21[48_0]
5-10	423-433	reinforced	_	_	_	_
5-11	434-446	QCT-mediated	abstract[33]	giv[33]	coref	8-11[54_33]
5-12	447-459	cytotoxicity	abstract[33]	giv[33]	_	_
5-13	460-463	and	_	_	_	_
5-14	464-476	QCT-mediated	abstract[34]	new[34]	coref	8-14[55_34]
5-15	477-486	apoptosis	abstract[34]	new[34]	_	_
5-16	487-489	in	_	_	_	_
5-17	490-496	SNU719	substance|object[36]	giv|giv[36]	coref|coref|coref|coref	8-17|8-17[57_36]|8-17|8-17[57_36]
5-18	497-502	cells	object[36]	giv[36]	_	_
5-19	503-504	.	_	_	_	_

#Text=Furthermore , the addition also activated the EBV lytic gene promoter and upregulated EBV genes .
6-1	505-516	Furthermore	_	_	_	_
6-2	517-518	,	_	_	_	_
6-3	519-522	the	abstract[37]	giv[37]	_	_
6-4	523-531	addition	abstract[37]	giv[37]	_	_
6-5	532-536	also	_	_	_	_
6-6	537-546	activated	_	_	_	_
6-7	547-550	the	abstract[40]	new[40]	coref	9-6[61_40]
6-8	551-554	EBV	place|abstract[40]	new|new[40]	coref	6-14
6-9	555-560	lytic	abstract[40]	new[40]	_	_
6-10	561-565	gene	abstract|abstract[40]	new|new[40]	coref	9-9
6-11	566-574	promoter	abstract[40]	new[40]	_	_
6-12	575-578	and	_	_	_	_
6-13	579-590	upregulated	_	_	_	_
6-14	591-594	EBV	abstract|abstract[42]	giv|new[42]	coref|coref|coref|coref	9-7|9-13[63_42]|9-7|9-13[63_42]
6-15	595-600	genes	abstract[42]	new[42]	_	_
6-16	601-602	.	_	_	_	_

#Text=Interestingly , ganoderic acid A ( GAA ) , an effective molecule of GLE also showed similar bioactive features with QCT like GLE .
7-1	603-616	Interestingly	_	_	_	_
7-2	617-618	,	_	_	_	_
7-3	619-628	ganoderic	_	_	_	_
7-4	629-633	acid	substance	new	_	_
7-5	634-635	A	_	_	_	_
7-6	636-637	(	_	_	_	_
7-7	638-641	GAA	object	new	coref	8-5[51_0]
7-8	642-643	)	_	_	_	_
7-9	644-645	,	_	_	_	_
7-10	646-648	an	object[45]	new[45]	_	_
7-11	649-658	effective	object[45]	new[45]	_	_
7-12	659-667	molecule	object[45]	new[45]	_	_
7-13	668-670	of	object[45]	new[45]	_	_
7-14	671-674	GLE	object[45]|substance	new[45]|giv	coref	7-23
7-15	675-679	also	_	_	_	_
7-16	680-686	showed	_	_	_	_
7-17	687-694	similar	abstract[47]	new[47]	_	_
7-18	695-704	bioactive	abstract[47]	new[47]	_	_
7-19	705-713	features	abstract[47]	new[47]	_	_
7-20	714-718	with	abstract[47]	new[47]	_	_
7-21	719-722	QCT	abstract[47]|substance[48]	new[47]|giv[48]	coref	8-8[0_48]
7-22	723-727	like	abstract[47]|substance[48]	new[47]|giv[48]	_	_
7-23	728-731	GLE	abstract[47]|substance[48]|substance	new[47]|giv[48]|giv	coref	9-17
7-24	732-733	.	_	_	_	_

#Text=The low concentrations of the GAA and QCT cotreatment reinforced QCT-mediated cytotoxicity and QCT-mediated apoptosis in SNU719 cells .
8-1	734-737	The	abstract[50]	new[50]	_	_
8-2	738-741	low	abstract[50]	new[50]	_	_
8-3	742-756	concentrations	abstract[50]	new[50]	_	_
8-4	757-759	of	abstract[50]	new[50]	_	_
8-5	760-763	the	abstract[50]|object[51]	new[50]|giv[51]	_	_
8-6	764-767	GAA	abstract[50]|object[51]	new[50]|giv[51]	_	_
8-7	768-771	and	abstract[50]	new[50]	_	_
8-8	772-775	QCT	abstract[50]|substance|abstract[53]	new[50]|giv|giv[53]	coref|coref|coref|coref	9-3[58_53]|10-1|9-3[58_53]|10-1
8-9	776-787	cotreatment	abstract[50]|abstract[53]	new[50]|giv[53]	_	_
8-10	788-798	reinforced	_	_	_	_
8-11	799-811	QCT-mediated	abstract[54]	giv[54]	_	_
8-12	812-824	cytotoxicity	abstract[54]	giv[54]	_	_
8-13	825-828	and	_	_	_	_
8-14	829-841	QCT-mediated	abstract[55]	giv[55]	coref	11-7[0_55]
8-15	842-851	apoptosis	abstract[55]	giv[55]	_	_
8-16	852-854	in	_	_	_	_
8-17	855-861	SNU719	substance|object[57]	giv|giv[57]	coref|coref	11-25[76_57]|11-25[76_57]
8-18	862-867	cells	object[57]	giv[57]	_	_
8-19	868-869	.	_	_	_	_

#Text=Furthermore , the cotreatment activated the EBV lytic gene promoter and upregulated EBV genes , like GLE .
9-1	870-881	Furthermore	_	_	_	_
9-2	882-883	,	_	_	_	_
9-3	884-887	the	abstract[58]	giv[58]	_	_
9-4	888-899	cotreatment	abstract[58]	giv[58]	_	_
9-5	900-909	activated	_	_	_	_
9-6	910-913	the	abstract[61]	giv[61]	_	_
9-7	914-917	EBV	place|abstract[61]	giv|giv[61]	coref	9-13
9-8	918-923	lytic	abstract[61]	giv[61]	_	_
9-9	924-928	gene	abstract|abstract[61]	giv|giv[61]	coref	23-12
9-10	929-937	promoter	abstract[61]	giv[61]	_	_
9-11	938-941	and	_	_	_	_
9-12	942-953	upregulated	_	_	_	_
9-13	954-957	EBV	abstract|abstract[63]	giv|giv[63]	coref|coref	14-8|14-8
9-14	958-963	genes	abstract[63]	giv[63]	_	_
9-15	964-965	,	_	_	_	_
9-16	966-970	like	_	_	_	_
9-17	971-974	GLE	substance	giv	coref	19-1
9-18	975-976	.	_	_	_	_

#Text=QCT has been shown to exhibit potential anticancer properties owing to its antiproliferative , growth factor suppressive and antioxidant effects .
10-1	977-980	QCT	substance	giv	ana	10-12
10-2	981-984	has	_	_	_	_
10-3	985-989	been	_	_	_	_
10-4	990-995	shown	_	_	_	_
10-5	996-998	to	_	_	_	_
10-6	999-1006	exhibit	_	_	_	_
10-7	1007-1016	potential	abstract[66]	new[66]	_	_
10-8	1017-1027	anticancer	abstract[66]	new[66]	_	_
10-9	1028-1038	properties	abstract[66]	new[66]	_	_
10-10	1039-1044	owing	_	_	_	_
10-11	1045-1047	to	_	_	_	_
10-12	1048-1051	its	substance|abstract[68]	giv|new[68]	coref|coref	11-4|11-4
10-13	1052-1069	antiproliferative	abstract[68]	new[68]	_	_
10-14	1070-1071	,	abstract[68]	new[68]	_	_
10-15	1072-1078	growth	abstract[68]	new[68]	_	_
10-16	1079-1085	factor	abstract[68]	new[68]	_	_
10-17	1086-1097	suppressive	abstract[69]	new[69]	coref	13-2[90_69]
10-18	1098-1101	and	abstract[69]	new[69]	_	_
10-19	1102-1113	antioxidant	abstract[69]	new[69]	_	_
10-20	1114-1121	effects	abstract[69]	new[69]	_	_
10-21	1122-1123	.	_	_	_	_

#Text=In addition , QCT can induce apoptosis , where it has been shown to reduce the growth of tumors and inhibit the spread of malignant cells .
11-1	1124-1126	In	_	_	_	_
11-2	1127-1135	addition	_	_	_	_
11-3	1136-1137	,	_	_	_	_
11-4	1138-1141	QCT	substance	giv	coref	13-6
11-5	1142-1145	can	_	_	_	_
11-6	1146-1152	induce	_	_	_	_
11-7	1153-1162	apoptosis	abstract	giv	ana	11-10
11-8	1163-1164	,	_	_	_	_
11-9	1165-1170	where	_	_	_	_
11-10	1171-1173	it	abstract	giv	ana	12-3
11-11	1174-1177	has	_	_	_	_
11-12	1178-1182	been	_	_	_	_
11-13	1183-1188	shown	_	_	_	_
11-14	1189-1191	to	_	_	_	_
11-15	1192-1198	reduce	_	_	_	_
11-16	1199-1202	the	event[73]	new[73]	_	_
11-17	1203-1209	growth	event[73]	new[73]	_	_
11-18	1210-1212	of	event[73]	new[73]	_	_
11-19	1213-1219	tumors	event[73]|object	new[73]|new	_	_
11-20	1220-1223	and	_	_	_	_
11-21	1224-1231	inhibit	_	_	_	_
11-22	1232-1235	the	event[75]	new[75]	_	_
11-23	1236-1242	spread	event[75]	new[75]	_	_
11-24	1243-1245	of	event[75]	new[75]	_	_
11-25	1246-1255	malignant	event[75]|object[76]	new[75]|giv[76]	coref	12-25[87_76]
11-26	1256-1261	cells	event[75]|object[76]	new[75]|giv[76]	_	_
11-27	1262-1263	.	_	_	_	_

#Text=Moreover , it inhibited chemical carcinogen-induced cell transformation , which was evident as cell viability decreased , ROS generation and microRNA-21 elevation occurred in cancer cells .
12-1	1264-1272	Moreover	_	_	_	_
12-2	1273-1274	,	_	_	_	_
12-3	1275-1277	it	abstract	giv	coref	16-1
12-4	1278-1287	inhibited	_	_	_	_
12-5	1288-1296	chemical	event[79]	new[79]	_	_
12-6	1297-1315	carcinogen-induced	event[79]	new[79]	_	_
12-7	1316-1320	cell	place|event[79]	new|new[79]	coref	12-14
12-8	1321-1335	transformation	event[79]	new[79]	_	_
12-9	1336-1337	,	_	_	_	_
12-10	1338-1343	which	_	_	_	_
12-11	1344-1347	was	_	_	_	_
12-12	1348-1355	evident	_	_	_	_
12-13	1356-1358	as	_	_	_	_
12-14	1359-1363	cell	place|event[81]	giv|new[81]	coref|coref	16-31|16-31
12-15	1364-1373	viability	event[81]	new[81]	_	_
12-16	1374-1383	decreased	_	_	_	_
12-17	1384-1385	,	_	_	_	_
12-18	1386-1389	ROS	substance|abstract[83]	new|new[83]	_	_
12-19	1390-1400	generation	abstract[83]	new[83]	_	_
12-20	1401-1404	and	_	_	_	_
12-21	1405-1416	microRNA-21	abstract|abstract[85]	new|new[85]	ana|ana	13-2[0_85]|13-2[0_85]
12-22	1417-1426	elevation	abstract[85]	new[85]	_	_
12-23	1427-1435	occurred	_	_	_	_
12-24	1436-1438	in	_	_	_	_
12-25	1439-1445	cancer	abstract|object[87]	new|giv[87]	coref|coref|coref|coref	16-11[112_87]|19-19|16-11[112_87]|19-19
12-26	1446-1451	cells	object[87]	giv[87]	_	_
12-27	1452-1453	.	_	_	_	_

#Text=Besides its antitumor effects , QCT has been shown to have antiviral activity through its anti-infective and anti-replicative abilities .
13-1	1454-1461	Besides	_	_	_	_
13-2	1462-1465	its	abstract|abstract[90]	giv|giv[90]	ana|coref|ana|coref	13-15|22-1[157_90]|13-15|22-1[157_90]
13-3	1466-1475	antitumor	abstract|abstract[90]	giv|giv[90]	coref	16-15
13-4	1476-1483	effects	abstract[90]	giv[90]	_	_
13-5	1484-1485	,	_	_	_	_
13-6	1486-1489	QCT	substance	giv	coref	14-16
13-7	1490-1493	has	_	_	_	_
13-8	1494-1498	been	_	_	_	_
13-9	1499-1504	shown	_	_	_	_
13-10	1505-1507	to	_	_	_	_
13-11	1508-1512	have	_	_	_	_
13-12	1513-1522	antiviral	abstract[92]	new[92]	_	_
13-13	1523-1531	activity	abstract[92]	new[92]	_	_
13-14	1532-1539	through	_	_	_	_
13-15	1540-1543	its	abstract|abstract[94]	giv|new[94]	_	_
13-16	1544-1558	anti-infective	abstract[94]	new[94]	_	_
13-17	1559-1562	and	abstract[94]	new[94]	_	_
13-18	1563-1579	anti-replicative	abstract[94]	new[94]	_	_
13-19	1580-1589	abilities	abstract[94]	new[94]	_	_
13-20	1590-1591	.	_	_	_	_

#Text=The replication of herpes viruses , including EBV , was found to be affected by QCT .
14-1	1592-1595	The	abstract[95]	new[95]	_	_
14-2	1596-1607	replication	abstract[95]	new[95]	_	_
14-3	1608-1610	of	abstract[95]	new[95]	_	_
14-4	1611-1617	herpes	abstract[95]|object|object[97]	new[95]|new|new[97]	_	_
14-5	1618-1625	viruses	abstract[95]|object[97]	new[95]|new[97]	_	_
14-6	1626-1627	,	abstract[95]|object[97]	new[95]|new[97]	_	_
14-7	1628-1637	including	abstract[95]|object[97]	new[95]|new[97]	_	_
14-8	1638-1641	EBV	abstract[95]|object[97]|object	new[95]|new[97]|giv	coref	15-10
14-9	1642-1643	,	_	_	_	_
14-10	1644-1647	was	_	_	_	_
14-11	1648-1653	found	_	_	_	_
14-12	1654-1656	to	_	_	_	_
14-13	1657-1659	be	_	_	_	_
14-14	1660-1668	affected	_	_	_	_
14-15	1669-1671	by	_	_	_	_
14-16	1672-1675	QCT	abstract	giv	coref	17-1
14-17	1676-1677	.	_	_	_	_

#Text=EBVaGC exhibits mixed characteristics of both gastric carcinoma and EBV .
15-1	1678-1684	EBVaGC	abstract|event[101]	giv|new[101]	coref|coref	16-11|16-11
15-2	1685-1693	exhibits	event[101]	new[101]	_	_
15-3	1694-1699	mixed	abstract[102]	new[102]	_	_
15-4	1700-1715	characteristics	abstract[102]	new[102]	_	_
15-5	1716-1718	of	abstract[102]	new[102]	_	_
15-6	1719-1723	both	abstract[102]|abstract[104]	new[102]|new[104]	coref	33-11[230_104]
15-7	1724-1731	gastric	abstract[102]|abstract|abstract[104]	new[102]|new|new[104]	coref	33-11
15-8	1732-1741	carcinoma	abstract[102]|abstract[104]	new[102]|new[104]	_	_
15-9	1742-1745	and	abstract[102]	new[102]	_	_
15-10	1746-1749	EBV	abstract[102]|abstract	new[102]|giv	coref	16-3
15-11	1750-1751	.	_	_	_	_

#Text=Apoptosis and EBV lytic reactivation can control the fate of EBVaGC cells , where antitumor agents can induce apoptosis and antiviral agents can stimulate EBV lytic reactivation to further aggravate cell lysis .
16-1	1752-1761	Apoptosis	abstract	giv	coref	16-19
16-2	1762-1765	and	_	_	_	_
16-3	1766-1769	EBV	abstract	giv	coref	16-25
16-4	1770-1775	lytic	abstract|event[109]	new|new[109]	coref|coref|coref|coref	16-26|16-25[119_109]|16-26|16-25[119_109]
16-5	1776-1788	reactivation	event[109]	new[109]	_	_
16-6	1789-1792	can	_	_	_	_
16-7	1793-1800	control	_	_	_	_
16-8	1801-1804	the	abstract[110]	new[110]	_	_
16-9	1805-1809	fate	abstract[110]	new[110]	_	_
16-10	1810-1812	of	abstract[110]	new[110]	_	_
16-11	1813-1819	EBVaGC	abstract[110]|substance|object[112]	new[110]|giv|giv[112]	coref|coref|coref|coref	17-9|19-18[136_112]|17-9|19-18[136_112]
16-12	1820-1825	cells	abstract[110]|object[112]	new[110]|giv[112]	_	_
16-13	1826-1827	,	_	_	_	_
16-14	1828-1833	where	_	_	_	_
16-15	1834-1843	antitumor	abstract|person[114]	giv|new[114]	coref|coref|coref|coref	16-21[116_114]|17-3[123_0]|16-21[116_114]|17-3[123_0]
16-16	1844-1850	agents	person[114]	new[114]	_	_
16-17	1851-1854	can	_	_	_	_
16-18	1855-1861	induce	_	_	_	_
16-19	1862-1871	apoptosis	abstract	giv	coref	21-18[154_0]
16-20	1872-1875	and	_	_	_	_
16-21	1876-1885	antiviral	person[116]	giv[116]	_	_
16-22	1886-1892	agents	person[116]	giv[116]	_	_
16-23	1893-1896	can	_	_	_	_
16-24	1897-1906	stimulate	_	_	_	_
16-25	1907-1910	EBV	abstract|event[119]	giv|giv[119]	coref|coref|coref|coref	21-22[156_119]|23-11|21-22[156_119]|23-11
16-26	1911-1916	lytic	abstract|event[119]	giv|giv[119]	coref	25-17
16-27	1917-1929	reactivation	event[119]	giv[119]	_	_
16-28	1930-1932	to	_	_	_	_
16-29	1933-1940	further	_	_	_	_
16-30	1941-1950	aggravate	_	_	_	_
16-31	1951-1955	cell	place|abstract[121]	giv|new[121]	coref|coref	26-25|26-25
16-32	1956-1961	lysis	abstract[121]	new[121]	_	_
16-33	1962-1963	.	_	_	_	_

#Text=QCT exhibits both antitumor and antiviral activities against EBVaGC .
17-1	1964-1967	QCT	substance	giv	coref	18-5
17-2	1968-1976	exhibits	_	_	_	_
17-3	1977-1981	both	abstract[123]|abstract[124]	giv[123]|giv[124]	coref|coref|coref|coref	31-4[0_123]|39-1[262_124]|31-4[0_123]|39-1[262_124]
17-4	1982-1991	antitumor	abstract[123]|abstract[124]	giv[123]|giv[124]	_	_
17-5	1992-1995	and	abstract[124]	giv[124]	_	_
17-6	1996-2005	antiviral	abstract[124]|abstract[125]	giv[124]|giv[125]	coref	31-4[209_125]
17-7	2006-2016	activities	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
17-8	2017-2024	against	_	_	_	_
17-9	2025-2031	EBVaGC	abstract	giv	coref	33-20
17-10	2032-2033	.	_	_	_	_

#Text=This dual function of QCT is likely to be synergistic .
18-1	2034-2038	This	abstract[127]	new[127]	coref	37-13[251_127]
18-2	2039-2043	dual	abstract[127]	new[127]	_	_
18-3	2044-2052	function	abstract[127]	new[127]	_	_
18-4	2053-2055	of	abstract[127]	new[127]	_	_
18-5	2056-2059	QCT	abstract[127]|abstract	new[127]|giv	coref	22-11
18-6	2060-2062	is	_	_	_	_
18-7	2063-2069	likely	_	_	_	_
18-8	2070-2072	to	_	_	_	_
18-9	2073-2075	be	_	_	_	_
18-10	2076-2087	synergistic	_	_	_	_
18-11	2088-2089	.	_	_	_	_

#Text=GLE , containing polysaccharides and triterpenes , is known to suppress the proliferation and metastatic potential of breast cancer cells by inhibiting Akt , AP-1 and NF-κB .
19-1	2090-2093	GLE	substance	giv	coref	20-3
19-2	2094-2095	,	_	_	_	_
19-3	2096-2106	containing	_	_	_	_
19-4	2107-2122	polysaccharides	substance	new	_	_
19-5	2123-2126	and	_	_	_	_
19-6	2127-2138	triterpenes	substance	new	_	_
19-7	2139-2140	,	_	_	_	_
19-8	2141-2143	is	_	_	_	_
19-9	2144-2149	known	_	_	_	_
19-10	2150-2152	to	_	_	_	_
19-11	2153-2161	suppress	_	_	_	_
19-12	2162-2165	the	abstract[132]	new[132]	coref	26-24[186_132]
19-13	2166-2179	proliferation	abstract[132]	new[132]	_	_
19-14	2180-2183	and	_	_	_	_
19-15	2184-2194	metastatic	_	_	_	_
19-16	2195-2204	potential	abstract[133]	new[133]	_	_
19-17	2205-2207	of	abstract[133]	new[133]	_	_
19-18	2208-2214	breast	abstract[133]|place|object[136]	new[133]|new|giv[136]	coref|coref|coref|coref	20-15|20-15[147_136]|20-15|20-15[147_136]
19-19	2215-2221	cancer	abstract[133]|abstract|object[136]	new[133]|giv|giv[136]	coref	20-16
19-20	2222-2227	cells	abstract[133]|object[136]	new[133]|giv[136]	_	_
19-21	2228-2230	by	_	_	_	_
19-22	2231-2241	inhibiting	_	_	_	_
19-23	2242-2245	Akt	substance	new	_	_
19-24	2246-2247	,	_	_	_	_
19-25	2248-2252	AP-1	quantity	new	_	_
19-26	2253-2256	and	_	_	_	_
19-27	2257-2262	NF-κB	quantity	new	_	_
19-28	2263-2264	.	_	_	_	_

#Text=Moreover , GLE modulated the estrogen receptor signaling and inhibited oxidative stress-induced invasiveness of breast cancer cells .
20-1	2265-2273	Moreover	_	_	_	_
20-2	2274-2275	,	_	_	_	_
20-3	2276-2279	GLE	substance	giv	coref	21-16
20-4	2280-2289	modulated	_	_	_	_
20-5	2290-2293	the	substance[141]	new[141]	_	_
20-6	2294-2302	estrogen	substance[141]	new[141]	_	_
20-7	2303-2311	receptor	substance|abstract[143]	new|new[143]	_	_
20-8	2312-2321	signaling	abstract[143]	new[143]	_	_
20-9	2322-2325	and	_	_	_	_
20-10	2326-2335	inhibited	_	_	_	_
20-11	2336-2345	oxidative	event[144]	new[144]	_	_
20-12	2346-2360	stress-induced	event[144]	new[144]	_	_
20-13	2361-2373	invasiveness	event[144]	new[144]	_	_
20-14	2374-2376	of	event[144]	new[144]	_	_
20-15	2377-2383	breast	event[144]|place|object[147]	new[144]|giv|giv[147]	coref|coref	32-18[225_147]|32-18[225_147]
20-16	2384-2390	cancer	event[144]|abstract|object[147]	new[144]|giv|giv[147]	coref	21-9[150_0]
20-17	2391-2396	cells	event[144]|object[147]	new[144]|giv[147]	_	_
20-18	2397-2398	.	_	_	_	_

#Text=Consistent with the results of previous studies on breast cancer , our study showed that GLE enhanced both QCT-mediated apoptosis and EBV-lytic reactivation .
21-1	2399-2409	Consistent	_	_	_	_
21-2	2410-2414	with	_	_	_	_
21-3	2415-2418	the	abstract[148]	new[148]	coref	25-3[170_148]
21-4	2419-2426	results	abstract[148]	new[148]	_	_
21-5	2427-2429	of	abstract[148]	new[148]	_	_
21-6	2430-2438	previous	abstract[148]|event[149]	new[148]|new[149]	coref	39-15[264_149]
21-7	2439-2446	studies	abstract[148]|event[149]	new[148]|new[149]	_	_
21-8	2447-2449	on	abstract[148]|event[149]	new[148]|new[149]	_	_
21-9	2450-2456	breast	abstract[148]|event[149]|abstract[150]	new[148]|new[149]|giv[150]	coref	28-9[0_150]
21-10	2457-2463	cancer	abstract[148]|event[149]|abstract[150]	new[148]|new[149]|giv[150]	_	_
21-11	2464-2465	,	_	_	_	_
21-12	2466-2469	our	person|abstract[152]	acc|giv[152]	coref|coref	35-2[237_152]|35-2[237_152]
21-13	2470-2475	study	abstract[152]	giv[152]	_	_
21-14	2476-2482	showed	_	_	_	_
21-15	2483-2487	that	_	_	_	_
21-16	2488-2491	GLE	substance	giv	coref	22-4
21-17	2492-2500	enhanced	_	_	_	_
21-18	2501-2505	both	abstract[154]|abstract[155]	giv[154]|new[155]	coref|coref|coref|coref	25-9[172_154]|36-12[245_155]|25-9[172_154]|36-12[245_155]
21-19	2506-2518	QCT-mediated	abstract[154]|abstract[155]	giv[154]|new[155]	_	_
21-20	2519-2528	apoptosis	abstract[154]|abstract[155]	giv[154]|new[155]	_	_
21-21	2529-2532	and	abstract[155]	new[155]	_	_
21-22	2533-2542	EBV-lytic	abstract[155]|event[156]	new[155]|giv[156]	coref	25-15[175_156]
21-23	2543-2555	reactivation	abstract[155]|event[156]	new[155]|giv[156]	_	_
21-24	2556-2557	.	_	_	_	_

#Text=The effects of GLE were evident at low concentrations of QCT .
22-1	2558-2561	The	abstract[157]	giv[157]	_	_
22-2	2562-2569	effects	abstract[157]	giv[157]	_	_
22-3	2570-2572	of	abstract[157]	giv[157]	_	_
22-4	2573-2576	GLE	abstract[157]|substance	giv[157]|giv	coref	24-13
22-5	2577-2581	were	_	_	_	_
22-6	2582-2589	evident	_	_	_	_
22-7	2590-2592	at	_	_	_	_
22-8	2593-2596	low	abstract[159]	new[159]	_	_
22-9	2597-2611	concentrations	abstract[159]	new[159]	_	_
22-10	2612-2614	of	abstract[159]	new[159]	_	_
22-11	2615-2618	QCT	abstract[159]|substance	new[159]|giv	coref	23-3
22-12	2619-2620	.	_	_	_	_

#Text=Furthermore , QCT also enhanced the GLE-mediated upregulation of the EBV gene expression .
23-1	2621-2632	Furthermore	_	_	_	_
23-2	2633-2634	,	_	_	_	_
23-3	2635-2638	QCT	abstract	giv	coref	24-6
23-4	2639-2643	also	_	_	_	_
23-5	2644-2652	enhanced	_	_	_	_
23-6	2653-2656	the	abstract[162]	new[162]	_	_
23-7	2657-2669	GLE-mediated	abstract[162]	new[162]	_	_
23-8	2670-2682	upregulation	abstract[162]	new[162]	_	_
23-9	2683-2685	of	abstract[162]	new[162]	_	_
23-10	2686-2689	the	abstract[162]|abstract[165]	new[162]|new[165]	_	_
23-11	2690-2693	EBV	abstract[162]|person|abstract[165]	new[162]|giv|new[165]	coref	33-6
23-12	2694-2698	gene	abstract[162]|abstract|abstract[165]	new[162]|giv|new[165]	_	_
23-13	2699-2709	expression	abstract[162]|abstract[165]	new[162]|new[165]	_	_
23-14	2710-2711	.	_	_	_	_

#Text=Similarly , the effects of QCT were evident at low concentrations of GLE .
24-1	2712-2721	Similarly	_	_	_	_
24-2	2722-2723	,	_	_	_	_
24-3	2724-2727	the	abstract[166]	new[166]	_	_
24-4	2728-2735	effects	abstract[166]	new[166]	_	_
24-5	2736-2738	of	abstract[166]	new[166]	_	_
24-6	2739-2742	QCT	abstract[166]|substance	new[166]|giv	coref	25-13
24-7	2743-2747	were	_	_	_	_
24-8	2748-2755	evident	_	_	_	_
24-9	2756-2758	at	_	_	_	_
24-10	2759-2762	low	animal[168]	new[168]	_	_
24-11	2763-2777	concentrations	animal[168]	new[168]	_	_
24-12	2778-2780	of	animal[168]	new[168]	_	_
24-13	2781-2784	GLE	animal[168]|substance	new[168]|giv	coref	25-7
24-14	2785-2786	.	_	_	_	_

#Text=Therefore , these results suggested that GLE enhanced QCT-mediated apoptosis , whereas QCT increased GLE-mediated EBV lytic reactivation .
25-1	2787-2796	Therefore	_	_	_	_
25-2	2797-2798	,	_	_	_	_
25-3	2799-2804	these	abstract[170]	giv[170]	_	_
25-4	2805-2812	results	abstract[170]	giv[170]	_	_
25-5	2813-2822	suggested	_	_	_	_
25-6	2823-2827	that	_	_	_	_
25-7	2828-2831	GLE	substance	giv	coref	30-1
25-8	2832-2840	enhanced	_	_	_	_
25-9	2841-2853	QCT-mediated	abstract[172]	giv[172]	ana	26-7[0_172]
25-10	2854-2863	apoptosis	abstract[172]	giv[172]	_	_
25-11	2864-2865	,	_	_	_	_
25-12	2866-2873	whereas	_	_	_	_
25-13	2874-2877	QCT	substance	giv	coref	35-5
25-14	2878-2887	increased	_	_	_	_
25-15	2888-2900	GLE-mediated	event[175]	giv[175]	coref	35-8[239_175]
25-16	2901-2904	EBV	event[175]	giv[175]	_	_
25-17	2905-2910	lytic	abstract|event[175]	giv|giv[175]	coref	36-17
25-18	2911-2923	reactivation	event[175]	giv[175]	_	_
25-19	2924-2925	.	_	_	_	_

#Text=Mycotherapy has several benefits , where it improves the overall response rate during cancer treatment , enhances immunity owing to the stimulation of T cell proliferation and reduces some chemotherapy-associated adverse events , such as nausea and insomnia .
26-1	2926-2937	Mycotherapy	event	new	_	_
26-2	2938-2941	has	_	_	_	_
26-3	2942-2949	several	abstract[177]	new[177]	_	_
26-4	2950-2958	benefits	abstract[177]	new[177]	_	_
26-5	2959-2960	,	_	_	_	_
26-6	2961-2966	where	_	_	_	_
26-7	2967-2969	it	abstract	giv	coref	36-12[244_0]
26-8	2970-2978	improves	_	_	_	_
26-9	2979-2982	the	abstract[180]	new[180]	_	_
26-10	2983-2990	overall	abstract[180]	new[180]	_	_
26-11	2991-2999	response	abstract|abstract[180]	new|new[180]	_	_
26-12	3000-3004	rate	abstract[180]	new[180]	_	_
26-13	3005-3011	during	abstract[180]	new[180]	_	_
26-14	3012-3018	cancer	abstract[180]|event[181]	new[180]|new[181]	coref	27-15[193_181]
26-15	3019-3028	treatment	abstract[180]|event[181]	new[180]|new[181]	_	_
26-16	3029-3030	,	_	_	_	_
26-17	3031-3039	enhances	_	_	_	_
26-18	3040-3048	immunity	abstract	new	_	_
26-19	3049-3054	owing	_	_	_	_
26-20	3055-3057	to	_	_	_	_
26-21	3058-3061	the	event[183]	new[183]	_	_
26-22	3062-3073	stimulation	event[183]	new[183]	_	_
26-23	3074-3076	of	event[183]	new[183]	_	_
26-24	3077-3078	T	event[183]|person|abstract[186]	new[183]|new|giv[186]	coref|coref	32-13[222_186]|32-13[222_186]
26-25	3079-3083	cell	event[183]|place|abstract[186]	new[183]|giv|giv[186]	_	_
26-26	3084-3097	proliferation	event[183]|abstract[186]	new[183]|giv[186]	_	_
26-27	3098-3101	and	_	_	_	_
26-28	3102-3109	reduces	_	_	_	_
26-29	3110-3114	some	abstract[187]	new[187]	_	_
26-30	3115-3138	chemotherapy-associated	abstract[187]	new[187]	_	_
26-31	3139-3146	adverse	abstract[187]	new[187]	_	_
26-32	3147-3153	events	abstract[187]	new[187]	_	_
26-33	3154-3155	,	abstract[187]	new[187]	_	_
26-34	3156-3160	such	abstract[187]	new[187]	_	_
26-35	3161-3163	as	abstract[187]	new[187]	_	_
26-36	3164-3170	nausea	abstract[187]|abstract	new[187]|new	_	_
26-37	3171-3174	and	abstract[187]	new[187]	_	_
26-38	3175-3183	insomnia	abstract[187]|abstract	new[187]|new	_	_
26-39	3184-3185	.	_	_	_	_

#Text=Medicinal mushrooms have mainly been used in Asian countries for hundreds of years for the treatment of infectious diseases .
27-1	3186-3195	Medicinal	plant[190]	new[190]	_	_
27-2	3196-3205	mushrooms	plant[190]	new[190]	_	_
27-3	3206-3210	have	_	_	_	_
27-4	3211-3217	mainly	_	_	_	_
27-5	3218-3222	been	_	_	_	_
27-6	3223-3227	used	_	_	_	_
27-7	3228-3230	in	_	_	_	_
27-8	3231-3236	Asian	place[191]	new[191]	ana	29-3[0_191]
27-9	3237-3246	countries	place[191]	new[191]	_	_
27-10	3247-3250	for	place[191]	new[191]	_	_
27-11	3251-3259	hundreds	place[191]|time[192]	new[191]|new[192]	_	_
27-12	3260-3262	of	place[191]|time[192]	new[191]|new[192]	_	_
27-13	3263-3268	years	place[191]|time[192]	new[191]|new[192]	_	_
27-14	3269-3272	for	_	_	_	_
27-15	3273-3276	the	event[193]	giv[193]	coref	28-9[197_193]
27-16	3277-3286	treatment	event[193]	giv[193]	_	_
27-17	3287-3289	of	event[193]	giv[193]	_	_
27-18	3290-3300	infectious	event[193]|abstract[194]	giv[193]|new[194]	ana	28-4[0_194]
27-19	3301-3309	diseases	event[193]|abstract[194]	giv[193]|new[194]	_	_
27-20	3310-3311	.	_	_	_	_

#Text=More recently , they have been used for cancer treatment as adjuncts .
28-1	3312-3316	More	_	_	_	_
28-2	3317-3325	recently	_	_	_	_
28-3	3326-3327	,	_	_	_	_
28-4	3328-3332	they	abstract	giv	_	_
28-5	3333-3337	have	_	_	_	_
28-6	3338-3342	been	_	_	_	_
28-7	3343-3347	used	_	_	_	_
28-8	3348-3351	for	_	_	_	_
28-9	3352-3358	cancer	abstract|event[197]	giv|giv[197]	coref|coref	31-7[210_0]|31-7[210_0]
28-10	3359-3368	treatment	event[197]	giv[197]	_	_
28-11	3369-3371	as	event[197]	giv[197]	_	_
28-12	3372-3380	adjuncts	event[197]	giv[197]	_	_
28-13	3381-3382	.	_	_	_	_

#Text=Importantly , they have an extensive clinical history of safe use as single agents or in combination with chemotherapy .
29-1	3383-3394	Importantly	_	_	_	_
29-2	3395-3396	,	_	_	_	_
29-3	3397-3401	they	place	giv	_	_
29-4	3402-3406	have	_	_	_	_
29-5	3407-3409	an	abstract[199]	new[199]	_	_
29-6	3410-3419	extensive	abstract[199]	new[199]	_	_
29-7	3420-3428	clinical	abstract[199]	new[199]	_	_
29-8	3429-3436	history	abstract[199]	new[199]	_	_
29-9	3437-3439	of	abstract[199]	new[199]	_	_
29-10	3440-3444	safe	abstract[199]|abstract[200]	new[199]|new[200]	coref	40-3[265_200]
29-11	3445-3448	use	abstract[199]|abstract[200]	new[199]|new[200]	_	_
29-12	3449-3451	as	abstract[199]|abstract[200]	new[199]|new[200]	_	_
29-13	3452-3458	single	abstract[199]|abstract[200]	new[199]|new[200]	_	_
29-14	3459-3465	agents	abstract[199]|abstract[200]	new[199]|new[200]	_	_
29-15	3466-3468	or	_	_	_	_
29-16	3469-3471	in	_	_	_	_
29-17	3472-3483	combination	abstract[201]	new[201]	_	_
29-18	3484-3488	with	abstract[201]	new[201]	_	_
29-19	3489-3501	chemotherapy	abstract[201]|substance	new[201]|new	coref	40-21[270_0]
29-20	3502-3503	.	_	_	_	_

#Text=GLE has been intensively combined with mycotherapy for the treatment of broad-spectrum cancers .
30-1	3504-3507	GLE	substance	giv	coref	31-1
30-2	3508-3511	has	_	_	_	_
30-3	3512-3516	been	_	_	_	_
30-4	3517-3528	intensively	_	_	_	_
30-5	3529-3537	combined	_	_	_	_
30-6	3538-3542	with	_	_	_	_
30-7	3543-3554	mycotherapy	abstract[204]	new[204]	_	_
30-8	3555-3558	for	abstract[204]	new[204]	_	_
30-9	3559-3562	the	abstract[204]|event[205]	new[204]|new[205]	_	_
30-10	3563-3572	treatment	abstract[204]|event[205]	new[204]|new[205]	_	_
30-11	3573-3575	of	abstract[204]|event[205]	new[204]|new[205]	_	_
30-12	3576-3590	broad-spectrum	abstract[204]|event[205]|abstract[206]	new[204]|new[205]|new[206]	_	_
30-13	3591-3598	cancers	abstract[204]|event[205]|abstract[206]	new[204]|new[205]|new[206]	_	_
30-14	3599-3600	.	_	_	_	_

#Text=GLE has shown antitumor activities against breast cancer , bladder cancer , prostate cancer , colorectal cancer and others .
31-1	3601-3604	GLE	substance	giv	coref	32-6
31-2	3605-3608	has	_	_	_	_
31-3	3609-3614	shown	_	_	_	_
31-4	3615-3624	antitumor	abstract|abstract[209]	giv|giv[209]	coref|coref	39-1[261_0]|39-1[261_0]
31-5	3625-3635	activities	abstract[209]	giv[209]	_	_
31-6	3636-3643	against	abstract[209]	giv[209]	_	_
31-7	3644-3650	breast	abstract[209]|abstract[210]	giv[209]|giv[210]	coref	31-10[212_210]
31-8	3651-3657	cancer	abstract[209]|abstract[210]	giv[209]|giv[210]	_	_
31-9	3658-3659	,	abstract[209]	giv[209]	_	_
31-10	3660-3667	bladder	abstract[209]|object|abstract[212]	giv[209]|new|giv[212]	coref|coref	31-13[214_212]|31-13[214_212]
31-11	3668-3674	cancer	abstract[209]|abstract[212]	giv[209]|giv[212]	_	_
31-12	3675-3676	,	abstract[209]	giv[209]	_	_
31-13	3677-3685	prostate	abstract[209]|place|abstract[214]	giv[209]|new|giv[214]	coref|coref	31-16[215_214]|31-16[215_214]
31-14	3686-3692	cancer	abstract[209]|abstract[214]	giv[209]|giv[214]	_	_
31-15	3693-3694	,	abstract[209]	giv[209]	_	_
31-16	3695-3705	colorectal	abstract[209]|abstract[215]	giv[209]|giv[215]	coref	32-18[0_215]
31-17	3706-3712	cancer	abstract[209]|abstract[215]	giv[209]|giv[215]	_	_
31-18	3713-3716	and	abstract[209]	giv[209]	_	_
31-19	3717-3723	others	abstract[209]|person	giv[209]|new	_	_
31-20	3724-3725	.	_	_	_	_

#Text=These tumor inhibitory effects of GLE were attributed to the disruption of the proliferation and metastasis of cancer cells .
32-1	3726-3731	These	abstract[219]	new[219]	_	_
32-2	3732-3737	tumor	abstract|abstract[219]	new|new[219]	_	_
32-3	3738-3748	inhibitory	abstract|abstract[219]	new|new[219]	_	_
32-4	3749-3756	effects	abstract[219]	new[219]	_	_
32-5	3757-3759	of	abstract[219]	new[219]	_	_
32-6	3760-3763	GLE	abstract[219]|substance	new[219]|giv	coref	36-5[241_0]
32-7	3764-3768	were	_	_	_	_
32-8	3769-3779	attributed	_	_	_	_
32-9	3780-3782	to	_	_	_	_
32-10	3783-3786	the	event[221]	new[221]	_	_
32-11	3787-3797	disruption	event[221]	new[221]	_	_
32-12	3798-3800	of	event[221]	new[221]	_	_
32-13	3801-3804	the	event[221]|abstract[222]	new[221]|giv[222]	_	_
32-14	3805-3818	proliferation	event[221]|abstract[222]	new[221]|giv[222]	_	_
32-15	3819-3822	and	event[221]	new[221]	_	_
32-16	3823-3833	metastasis	event[221]|abstract[223]	new[221]|new[223]	_	_
32-17	3834-3836	of	event[221]|abstract[223]	new[221]|new[223]	_	_
32-18	3837-3843	cancer	event[221]|abstract[223]|abstract|object[225]	new[221]|new[223]|giv|giv[225]	_	_
32-19	3844-3849	cells	event[221]|abstract[223]|object[225]	new[221]|new[223]|giv[225]	_	_
32-20	3850-3851	.	_	_	_	_

#Text=However , the fact that EBV is the initiator of gastric carcinoma should be considered in the treatment of EBVaGC .
33-1	3852-3859	However	abstract[226]	new[226]	_	_
33-2	3860-3861	,	abstract[226]	new[226]	_	_
33-3	3862-3865	the	abstract[226]	new[226]	_	_
33-4	3866-3870	fact	abstract[226]	new[226]	_	_
33-5	3871-3875	that	abstract[226]	new[226]	_	_
33-6	3876-3879	EBV	abstract[226]|abstract	new[226]|giv	coref	33-8[228_0]
33-7	3880-3882	is	abstract[226]	new[226]	_	_
33-8	3883-3886	the	abstract[226]|abstract[228]	new[226]|giv[228]	coref	34-1[0_228]
33-9	3887-3896	initiator	abstract[226]|abstract[228]	new[226]|giv[228]	_	_
33-10	3897-3899	of	abstract[226]|abstract[228]	new[226]|giv[228]	_	_
33-11	3900-3907	gastric	abstract[226]|abstract[228]|abstract|abstract[230]	new[226]|giv[228]|giv|giv[230]	_	_
33-12	3908-3917	carcinoma	abstract[226]|abstract[228]|abstract[230]	new[226]|giv[228]|giv[230]	_	_
33-13	3918-3924	should	abstract[226]	new[226]	_	_
33-14	3925-3927	be	abstract[226]	new[226]	_	_
33-15	3928-3938	considered	abstract[226]	new[226]	_	_
33-16	3939-3941	in	_	_	_	_
33-17	3942-3945	the	event[231]	new[231]	coref	37-23[253_231]
33-18	3946-3955	treatment	event[231]	new[231]	_	_
33-19	3956-3958	of	event[231]	new[231]	_	_
33-20	3959-3965	EBVaGC	event[231]|abstract	new[231]|giv	coref	34-10
33-21	3966-3967	.	_	_	_	_

#Text=EBV should be eliminated to reduce the risk of EBVaGC relapse .
34-1	3968-3971	EBV	abstract	giv	coref	36-16
34-2	3972-3978	should	_	_	_	_
34-3	3979-3981	be	_	_	_	_
34-4	3982-3992	eliminated	_	_	_	_
34-5	3993-3995	to	_	_	_	_
34-6	3996-4002	reduce	_	_	_	_
34-7	4003-4006	the	abstract[234]	new[234]	_	_
34-8	4007-4011	risk	abstract[234]	new[234]	_	_
34-9	4012-4014	of	abstract[234]	new[234]	_	_
34-10	4015-4021	EBVaGC	abstract[234]|abstract|abstract[236]	new[234]|giv|new[236]	coref|coref	37-23|37-23
34-11	4022-4029	relapse	abstract[234]|abstract[236]	new[234]|new[236]	_	_
34-12	4030-4031	.	_	_	_	_

#Text=In this study , QCT strongly induced EBV lytic reactivation .
35-1	4032-4034	In	_	_	_	_
35-2	4035-4039	this	abstract[237]	giv[237]	_	_
35-3	4040-4045	study	abstract[237]	giv[237]	_	_
35-4	4046-4047	,	_	_	_	_
35-5	4048-4051	QCT	substance	giv	coref	36-8
35-6	4052-4060	strongly	_	_	_	_
35-7	4061-4068	induced	_	_	_	_
35-8	4069-4072	EBV	event[239]	giv[239]	coref	36-15[248_239]
35-9	4073-4078	lytic	event[239]	giv[239]	_	_
35-10	4079-4091	reactivation	event[239]	giv[239]	_	_
35-11	4092-4093	.	_	_	_	_

#Text=The synergistic effects of the GLE and QCT cotreatment might enhance QCT-mediated apoptosis and GLE-mediated EBV lytic reactivation .
36-1	4094-4097	The	abstract[240]	new[240]	coref	39-5[263_240]
36-2	4098-4109	synergistic	abstract[240]	new[240]	_	_
36-3	4110-4117	effects	abstract[240]	new[240]	_	_
36-4	4118-4120	of	abstract[240]	new[240]	_	_
36-5	4121-4124	the	abstract[240]|substance[241]	new[240]|giv[241]	coref	37-3[250_241]
36-6	4125-4128	GLE	abstract[240]|substance[241]	new[240]|giv[241]	_	_
36-7	4129-4132	and	abstract[240]|substance[241]	new[240]|giv[241]	_	_
36-8	4133-4136	QCT	abstract[240]|substance[241]|substance|abstract[243]	new[240]|giv[241]|giv|new[243]	coref|coref	40-9|40-9
36-9	4137-4148	cotreatment	abstract[240]|substance[241]|abstract[243]	new[240]|giv[241]|new[243]	_	_
36-10	4149-4154	might	_	_	_	_
36-11	4155-4162	enhance	_	_	_	_
36-12	4163-4175	QCT-mediated	abstract[244]|abstract[245]	giv[244]|giv[245]	_	_
36-13	4176-4185	apoptosis	abstract[244]|abstract[245]	giv[244]|giv[245]	_	_
36-14	4186-4189	and	abstract[245]	giv[245]	_	_
36-15	4190-4202	GLE-mediated	abstract[245]|event[248]	giv[245]|giv[248]	_	_
36-16	4203-4206	EBV	abstract[245]|abstract|event[248]	giv[245]|giv|giv[248]	_	_
36-17	4207-4212	lytic	abstract[245]|abstract|event[248]	giv[245]|giv|giv[248]	_	_
36-18	4213-4225	reactivation	abstract[245]|event[248]	giv[245]|giv[248]	_	_
36-19	4226-4227	.	_	_	_	_

#Text=Therefore , QCT-supplemented GLE might be used as a medicinal food with a dual function as an antitumor and antiviral agent for EBVaGC treatment .
37-1	4228-4237	Therefore	_	_	_	_
37-2	4238-4239	,	_	_	_	_
37-3	4240-4256	QCT-supplemented	event|substance[250]	new|giv[250]	coref|coref|coref|coref	38-15|38-15[259_250]|38-15|38-15[259_250]
37-4	4257-4260	GLE	substance[250]	giv[250]	_	_
37-5	4261-4266	might	_	_	_	_
37-6	4267-4269	be	_	_	_	_
37-7	4270-4274	used	_	_	_	_
37-8	4275-4277	as	_	_	_	_
37-9	4278-4279	a	_	_	_	_
37-10	4280-4289	medicinal	_	_	_	_
37-11	4290-4294	food	_	_	_	_
37-12	4295-4299	with	_	_	_	_
37-13	4300-4301	a	abstract[251]	giv[251]	ana	38-7[0_251]
37-14	4302-4306	dual	abstract[251]	giv[251]	_	_
37-15	4307-4315	function	abstract[251]	giv[251]	_	_
37-16	4316-4318	as	abstract[251]	giv[251]	_	_
37-17	4319-4321	an	abstract[251]	giv[251]	_	_
37-18	4322-4331	antitumor	abstract[251]	giv[251]	_	_
37-19	4332-4335	and	abstract[251]	giv[251]	_	_
37-20	4336-4345	antiviral	abstract[251]	giv[251]	_	_
37-21	4346-4351	agent	abstract[251]	giv[251]	_	_
37-22	4352-4355	for	abstract[251]	giv[251]	_	_
37-23	4356-4362	EBVaGC	abstract[251]|abstract|event[253]	giv[251]|giv|giv[253]	coref|coref|coref|coref	38-22|40-14[268_253]|38-22|40-14[268_253]
37-24	4363-4372	treatment	abstract[251]|event[253]	giv[251]|giv[253]	_	_
37-25	4373-4374	.	_	_	_	_

#Text=To the author ’s knowledge , this is the first study to report that QCT-supplemented GLE might be effective in treating EBVaGC .
38-1	4375-4377	To	_	_	_	_
38-2	4378-4381	the	abstract[255]	new[255]	_	_
38-3	4382-4388	author	person[254]|abstract[255]	new[254]|new[255]	_	_
38-4	4389-4391	’s	person[254]|abstract[255]	new[254]|new[255]	_	_
38-5	4392-4401	knowledge	abstract[255]	new[255]	_	_
38-6	4402-4403	,	_	_	_	_
38-7	4404-4408	this	abstract	giv	coref	38-9[257_0]
38-8	4409-4411	is	_	_	_	_
38-9	4412-4415	the	abstract[257]	giv[257]	coref	40-25[272_257]
38-10	4416-4421	first	abstract[257]	giv[257]	_	_
38-11	4422-4427	study	abstract[257]	giv[257]	_	_
38-12	4428-4430	to	_	_	_	_
38-13	4431-4437	report	_	_	_	_
38-14	4438-4442	that	_	_	_	_
38-15	4443-4459	QCT-supplemented	event|substance[259]	giv|giv[259]	coref|coref	40-7[0_259]|40-7[0_259]
38-16	4460-4463	GLE	substance[259]	giv[259]	_	_
38-17	4464-4469	might	_	_	_	_
38-18	4470-4472	be	_	_	_	_
38-19	4473-4482	effective	_	_	_	_
38-20	4483-4485	in	_	_	_	_
38-21	4486-4494	treating	_	_	_	_
38-22	4495-4501	EBVaGC	abstract	giv	_	_
38-23	4502-4503	.	_	_	_	_

#Text=The synergistic antitumor and antiviral effects were supported by both in vivo and in vitro studies .
39-1	4504-4507	The	abstract[261]|abstract[262]	giv[261]|giv[262]	coref|coref	41-16[275_261]|41-16[275_261]
39-2	4508-4519	synergistic	abstract[261]|abstract[262]	giv[261]|giv[262]	_	_
39-3	4520-4529	antitumor	abstract[261]|abstract[262]	giv[261]|giv[262]	_	_
39-4	4530-4533	and	abstract[262]	giv[262]	_	_
39-5	4534-4543	antiviral	abstract[262]|abstract[263]	giv[262]|giv[263]	_	_
39-6	4544-4551	effects	abstract[262]|abstract[263]	giv[262]|giv[263]	_	_
39-7	4552-4556	were	_	_	_	_
39-8	4557-4566	supported	_	_	_	_
39-9	4567-4569	by	_	_	_	_
39-10	4570-4574	both	_	_	_	_
39-11	4575-4577	in	_	_	_	_
39-12	4578-4582	vivo	_	_	_	_
39-13	4583-4586	and	_	_	_	_
39-14	4587-4589	in	_	_	_	_
39-15	4590-4595	vitro	event[264]	giv[264]	coref	41-3[273_264]
39-16	4596-4603	studies	event[264]	giv[264]	_	_
39-17	4604-4605	.	_	_	_	_

#Text=Hence , the combined use of GLE and QCT could be beneficial in cancer treatment by alleviating the toxicity of conventional chemotherapy and improving the immune function .
40-1	4606-4611	Hence	_	_	_	_
40-2	4612-4613	,	_	_	_	_
40-3	4614-4617	the	abstract[265]	giv[265]	_	_
40-4	4618-4626	combined	abstract[265]	giv[265]	_	_
40-5	4627-4630	use	abstract[265]	giv[265]	_	_
40-6	4631-4633	of	abstract[265]	giv[265]	_	_
40-7	4634-4637	GLE	abstract[265]|substance	giv[265]|giv	coref	41-22[277_0]
40-8	4638-4641	and	abstract[265]	giv[265]	_	_
40-9	4642-4645	QCT	abstract[265]|substance	giv[265]|giv	_	_
40-10	4646-4651	could	_	_	_	_
40-11	4652-4654	be	_	_	_	_
40-12	4655-4665	beneficial	_	_	_	_
40-13	4666-4668	in	_	_	_	_
40-14	4669-4675	cancer	event[268]	giv[268]	_	_
40-15	4676-4685	treatment	event[268]	giv[268]	_	_
40-16	4686-4688	by	_	_	_	_
40-17	4689-4700	alleviating	_	_	_	_
40-18	4701-4704	the	abstract[269]	new[269]	_	_
40-19	4705-4713	toxicity	abstract[269]	new[269]	_	_
40-20	4714-4716	of	abstract[269]	new[269]	_	_
40-21	4717-4729	conventional	abstract[269]|substance[270]	new[269]|giv[270]	_	_
40-22	4730-4742	chemotherapy	abstract[269]|substance[270]	new[269]|giv[270]	_	_
40-23	4743-4746	and	_	_	_	_
40-24	4747-4756	improving	_	_	_	_
40-25	4757-4760	the	abstract[272]	giv[272]	_	_
40-26	4761-4767	immune	abstract|abstract[272]	new|giv[272]	_	_
40-27	4768-4776	function	abstract[272]	giv[272]	_	_
40-28	4777-4778	.	_	_	_	_

#Text=However , more studies are still needed to further elucidate the molecular mechanisms of the direct antitumor and antiviral effects of QCT-supplemented GLE .
41-1	4779-4786	However	_	_	_	_
41-2	4787-4788	,	_	_	_	_
41-3	4789-4793	more	event[273]	giv[273]	_	_
41-4	4794-4801	studies	event[273]	giv[273]	_	_
41-5	4802-4805	are	_	_	_	_
41-6	4806-4811	still	_	_	_	_
41-7	4812-4818	needed	_	_	_	_
41-8	4819-4821	to	_	_	_	_
41-9	4822-4829	further	_	_	_	_
41-10	4830-4839	elucidate	_	_	_	_
41-11	4840-4843	the	abstract[274]	new[274]	_	_
41-12	4844-4853	molecular	abstract[274]	new[274]	_	_
41-13	4854-4864	mechanisms	abstract[274]	new[274]	_	_
41-14	4865-4867	of	abstract[274]	new[274]	_	_
41-15	4868-4871	the	abstract[274]|abstract[276]	new[274]|new[276]	_	_
41-16	4872-4878	direct	abstract[274]|abstract[275]|abstract[276]	new[274]|giv[275]|new[276]	_	_
41-17	4879-4888	antitumor	abstract[274]|abstract[275]|abstract[276]	new[274]|giv[275]|new[276]	_	_
41-18	4889-4892	and	abstract[274]|abstract[276]	new[274]|new[276]	_	_
41-19	4893-4902	antiviral	abstract[274]|abstract[276]	new[274]|new[276]	_	_
41-20	4903-4910	effects	abstract[274]|abstract[276]	new[274]|new[276]	_	_
41-21	4911-4913	of	abstract[274]|abstract[276]	new[274]|new[276]	_	_
41-22	4914-4930	QCT-supplemented	abstract[274]|abstract[276]|substance[277]	new[274]|new[276]|giv[277]	_	_
41-23	4931-4934	GLE	abstract[274]|abstract[276]|substance[277]	new[274]|new[276]|giv[277]	_	_
41-24	4935-4936	.	_	_	_	_
